As a long-running battle over access to a pricey cystic fibrosis drug grinds on in the U.K., an advocacy group and several families have formed a buyer’s club in order to make a lower-cost version of a Vertex (VRTX) Pharmaceuticals (VRTX) treatment available to patients in the next few weeks.

The new buyer’s club is working with Gador, a drug maker based in Argentina, which will ship a generic version of the Orkambi medication to the U.K., where cystic fibrosis patients and their families can expect to pay roughly $25,000 a year, depending on how many people sign up. This would be 80 percent less than the approximately $132,000 that Vertex reportedly wants to charge the National Health Service in England.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy